Stock Split Watch: Is Eli Lilly Next?

Stock Split Watch: Is Eli Lilly Next? frames growing investor debate as Lilly's stock nears $1,000 following a sustained rally in the GLP-1 obesity drug market. Lilly now controls about 60% of the U.S. GLP-1 drug market, a dominant position that has driven strong revenue growth and a share-price advance. Over the past three years, Lilly's stock has risen more than 160%, and in the past month it pushed past the $1,000 mark. The move prompts questions about whether a stock split could be used to widen ownership and improve liquidity without altering the company's fundamentals. Market observers often point to splits at Nvidia and Walmart as context for why Lilly might consider such a move when valuations heat up. Lilly has split its stock four times in the past, with the last split occurring in the late 1990s; management changes since then may shift the strategic calculus. Although the stock exceeding $1,000 is a notable milestone, the article notes that price alone has not triggered a split in Lilly's history, and decisions depend on management's capital-allocation priorities. Despite the milestone, investors will monitor signals from leadership about growth prospects and capital allocation to gauge whether a split becomes part of Lilly's strategy.